One-Month Dual Antiplatelet Therapy in Patients With Chronic and Acute Coronary Syndromes Treated With Bioresorbable Polymer Everolimus-Eluting Stents.

Autores de IIS La Fe

• Jorge Sanz Sánchez

  Autor

Participantes ajenos a IIS La Fe

• Musto, Carmine
• Paolucci, Luca
• Pivato, Carlo Andrea
• Testa, Luca
• Pacchioni, Andrea
• Briguori, Carlo
• Esposito, Giovanni
• Piccolo, Raffaele
• Lucisano, Luigi
• De Luca, Leonardo
• Conrotto, Federico
• Cesario, Vincenzo
• De Felice, Francesco
• Latini, Alessia Chiara
• Regazzoli, Damiano
• Sardella, Gennaro
• Indolfi, Ciro
• Reimers, Bernhard
• Condorelli, Gianluigi
• Stefanini, Giulio

Grupos

• Grupo de Investigación Clínica y Traslacional en Cardiología

  

  Investigador Principal

  Esther Roselló Lletí

Abstract

There is a paucity of data regarding the safety of a 1-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients at high bleeding risk (HBR) presenting with acute coronary syndromes (ACS). We aimed to compare the clinical outcomes of patients at HBR with chronic coronary syndrome (CCS) or ACS treated with PCI using bioresorbable polymer everolimus-eluting stent (BP-EES) followed by 1-month DAPT. Patients at HBR who underwent PCI with BP-EES were prospectively enrolled in 10 Italian centers. All patients were treated with 1-month DAPT. In case of need for anticoagulation, patients received an oral anticoagulant in addition to a P2Y12 inhibitor for 1month, followed by oral anticoagulation only after that. The primary end point was a composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis at 12months. Overall, 263 patients (59.4%) with CCS and 180 patients (40.6%) with ACS were enrolled. No significant difference was evident between patients with CCS and ACS for the primary end point (4.3% vs 5.6%, respectively, p=0.497) and for each isolated component. The risk for Bleeding Academic Research Consortium (BARC) type 1 to 5 or type 3 to 5 bleedings was also similar between patients with CCS and ACS (4.3% vs 5.2%, p=0.677, and 1.6% vs 2.9%, p=0.351, respectively). In conclusion, among HBR patients with ACS who underwent PCI with BP-EES, a 1-month DAPT strategy is associated with a similar risk of ischemic and bleeding events compared with those with CCS.

Copyright © 2023 Elsevier Inc. All rights reserved.

Keywords

• acute coronary syndromes; high bleeding risk; percutaneous coronary interventions; short DAPT